JP2025508009A5 - - Google Patents

Info

Publication number
JP2025508009A5
JP2025508009A5 JP2024552760A JP2024552760A JP2025508009A5 JP 2025508009 A5 JP2025508009 A5 JP 2025508009A5 JP 2024552760 A JP2024552760 A JP 2024552760A JP 2024552760 A JP2024552760 A JP 2024552760A JP 2025508009 A5 JP2025508009 A5 JP 2025508009A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024552760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508009A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/055129 external-priority patent/WO2023169896A1/en
Publication of JP2025508009A publication Critical patent/JP2025508009A/ja
Publication of JP2025508009A5 publication Critical patent/JP2025508009A5/ja
Pending legal-status Critical Current

Links

JP2024552760A 2022-03-09 2023-03-01 FRαに対する結合分子 Pending JP2025508009A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263269068P 2022-03-09 2022-03-09
US63/269,068 2022-03-09
PCT/EP2023/055129 WO2023169896A1 (en) 2022-03-09 2023-03-01 BINDING MOLECULES AGAINST FRα

Publications (2)

Publication Number Publication Date
JP2025508009A JP2025508009A (ja) 2025-03-21
JP2025508009A5 true JP2025508009A5 (https=) 2026-03-06

Family

ID=85476154

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024552760A Pending JP2025508009A (ja) 2022-03-09 2023-03-01 FRαに対する結合分子

Country Status (15)

Country Link
US (1) US20230295293A1 (https=)
EP (1) EP4489859A1 (https=)
JP (1) JP2025508009A (https=)
KR (1) KR20240159839A (https=)
CN (1) CN118843642A (https=)
AR (1) AR128686A1 (https=)
AU (1) AU2023229884A1 (https=)
CA (1) CA3253515A1 (https=)
CL (1) CL2024002658A1 (https=)
CO (1) CO2024013569A2 (https=)
CR (1) CR20240415A (https=)
IL (1) IL315308A (https=)
MX (1) MX2024010956A (https=)
TW (1) TW202400644A (https=)
WO (1) WO2023169896A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120936382A (zh) * 2023-02-16 2025-11-11 阿斯利康(瑞典)有限公司 采用治疗性结合分子治疗癌症的组合疗法
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US12378314B1 (en) 2024-02-02 2025-08-05 Medicovestor, Inc. Proteins that bind folate receptor alpha including fully-human antibodies
US12258396B1 (en) * 2024-02-02 2025-03-25 Medicovestor, Inc. Methods of using immunotherapeutics that bind folate receptor alpha
WO2025210264A1 (en) 2024-04-04 2025-10-09 Merck Patent Gmbh Antibody-drug-conjugates binding napi2b
WO2026057740A1 (en) 2024-09-12 2026-03-19 Astrazeneca Ab Treatment of cancer with therapeutic binding molecules
CN120842412B (zh) * 2025-09-23 2025-12-05 合肥综合性国家科学中心大健康研究院 一种靶向人的叶酸受体α的单克隆抗体及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0871490T3 (da) 1995-12-22 2003-07-07 Bristol Myers Squibb Co Forgrenede hydrazonlinkere
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7776814B2 (en) 2002-07-09 2010-08-17 R&D-Biopharmaceuticals Gmbh Tubulysin conjugates
DK1523493T3 (da) 2002-07-09 2013-12-02 Alexander Doemling Nye tubulysinanaloge
DE10254439A1 (de) 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysine, Herstellungsverfahren und Tubulysin-Mittel
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
CL2008001334A1 (es) 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
US8476451B2 (en) 2007-07-20 2013-07-02 The Regents Of The University Of California Tubulysin D analogues
EP2181101A2 (en) 2007-07-20 2010-05-05 Helmholtz-Zentrum für Infektionsforschung GmbH Tubulysin d analogues
NZ584514A (en) 2007-10-19 2012-07-27 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
CN101909441B (zh) 2007-10-25 2015-05-13 恩多塞特公司 微管蛋白抑制剂及其制备方法
JP2013535220A (ja) 2010-08-06 2013-09-12 エンドサイト,インコーポレイテッド ツブリシンを調製するためのプロセス
WO2013130776A1 (en) * 2012-02-29 2013-09-06 Purdue Research Foundation Folate receptor alpha binding ligands
SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
WO2015155345A1 (en) 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
KR20250035037A (ko) * 2017-09-18 2025-03-11 서트로 바이오파마, 인크. 항-엽산 수용체 알파 항체 접합체 및 이의 용도
MX2021011812A (es) 2019-03-29 2021-10-22 Medimmune Ltd Compuestos y conjugados de estos.
MA55818A (fr) 2019-04-29 2022-03-16 Immunogen Inc Anticorps et immunoconjugués de fr-alpha biparatopique

Similar Documents

Publication Publication Date Title
JP2025508009A5 (https=)
JP7146031B2 (ja) 抗her2抗体-薬物コンジュゲート
JP7467610B2 (ja) カンプトテシン誘導体及びその複合体
US20240409628A1 (en) Antibody, antibody-drug conjugate thereof and use thereof
US20230293536A1 (en) Anti-erbb2 antibody-drug conjugate and composition thereof, preparation method therefor, and application thereof
JP6449366B2 (ja) 抗trop2抗体−薬物コンジュゲート
CA2946796C (en) Antibody-drug-conjugate and its use for the treatment of cancer
US20230340158A1 (en) Anti-vegf-anti-pd-l1 bispecific antibody, pharmaceutical composition of same, and uses thereof
US20140363454A1 (en) Antibody-Drug Conjugates, Compositions and Methods of Use
TW202537975A (zh) 抗體-藥物結合物之製造方法
TW201609152A (zh) 包含細胞結合劑及細胞毒性劑之偶聯物
KR102949500B1 (ko) 접합을 위한 폴리펩티드 복합체 및 이의 용도
JP7675818B2 (ja) 抗クローディン-18.2抗体及びその抗体薬物複合体
JP2020532523A (ja) 抗egfr抗体薬物コンジュゲート(adc)及びその使用
CN113121639A (zh) 澳瑞他汀类似物及其偶联物、其制备方法及其应用
JP2024545170A5 (https=)
US12156918B2 (en) Neuroendocrine cancer targeted therapy
CN105828841A (zh) 抗-efna4抗体-药物缀合物
JP2025508779A5 (https=)
CN119300868B (zh) 喜树碱类化合物及其偶联物、其制备方法和用途
CN119053607B (zh) 喜树碱类化合物及其偶联物、其制备方法和用途
CN118591544A (zh) 用于制备抗体药物偶联物的连接子、化合物及用途
WO2025106658A1 (en) 5t4 antibody drug conjugates and methods of their use
TW202610690A (zh) 靶向cdh3之抗體-藥物結合物及其製備方法及用途
WO2025168066A1 (zh) 喜树碱类化合物及其偶联物、其制备方法和用途